News
![novartis innit](https://pharmaphorum.com/wp-content/uploads/2019/10/novartis-innit.jpg)
Novartis agrees $245m settlement over Exforge generics delay
Novartis has said it will pay $245 million to resolve civil litigation in the US, which accuses it of a 'pay for delay' scheme involving generics of its high blood pressure therapy Exforge.